Background choroidal neovascularization (CNV) is the common reason of visual acuity impairment in high myopia patients,which usually leads to irreversible central visual impairment.Objective This study was to evaluate the clinical efficacy and safety of conbercept intravitreal injection for CNV in high myopia.Methods Fifteen high myopia patients with macular CNV diagnosed by OCT and fluorescein fundus angiography (FFA) from July 2014 to July 2015 were retrospectively analyzed.All patients were performed with intravitreal injection of conbercept 0.5 mg (0.05 ml).The best corrected visual acuity (BCVA) and central macular thickness (CMT) were examined 1 day,l week,4,8 and 12 weeks after injection.The ocular and systemic complications relating to drug were also observed.Results Fifteen eyes of 15 patients totally received 45 times of conbercept intravitreal injection.Among the total,1 eye only received 1 time of treatment,2 eyes received 2 times of treatment,12 eyes received 3 times of treatment and 1 eye received 4 times of treatments.After 12 weeks of treatment,FFA showed that fluorescein leakage disappeared in 10 eyes;fluorescein leakage area decreased in 4 eyes;fluorescein leakage was continued in 1 eye.The BCVA before treatment and at 4,8 and 12 weeks after treatment were 0.61 ±0.46,0.60±0.43,0.41±0.53 and 0.41±0.51,with significant difference among them (F=7.862,P＜0.001).The CMT before treatment and at 4,8 and 12 weeks after treatment were (280.33±14.40),(269.00±10.10),(261.93±7.80) and (259.53±6.30) μm respectively,with significant difference among them (F =32.520,P＜0.001).None of the patients conducted anterior chamber puncture because of elevated intraocular pressure,and no intraocular inflammation,vitreous hemorrhage,retinal detachment and cardiovascular disease or other serious complications occurred.Conclusions Intravitreal injection of conbercept can relieve macular edema and improve the vision.It is an effective method for the treatment of CNV associated with high myopia,but long-term follow-up observation still need to perform.%背景 脉络膜新生血管(CNV)形成是引起高度近视眼视力障碍的原因之一,可导致视功能的不可逆性损害. 目的 观察康柏西普玻璃体腔注射治疗高度近视CNV的临床疗效及安全性. 方法 对2014年7月至2015年7月在天津医科大学眼科医院采用康柏西普玻璃体腔注射治疗的高度近视CNV患者15例15眼的临床资料进行回顾性分析,患眼行眼科常规检查、OCT、荧光素眼底血管造影(FFA)检查后,均接受0.05 ml康柏西普玻璃体腔注射,分别于注射后1d及注射后1、4、8和12周观察患者最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)变化,并观察药物相关的眼部和全身并发症.结果 15眼共接受康柏西普玻璃体腔注射45次,其中1眼注射1次,2眼注射2次,12眼注射3次,1眼注射4次.注射后12周,FFA显示有10眼荧光素渗漏消失,4眼荧光素渗漏面积减小,1眼发现出血,荧光素持续渗漏.注射前和注射后第4、8、12周的BCVA分别为0.61±0.46、0.60±0.43、0.41±0.53和0.41±0.51,总体比较差异有统计学意义(F=7.862,P＜0.001);患眼注射前平均CMT为(280.33±14.40) μm,注射后第4、8、12周分别为(269.00±10.10)、(261.93±7.80)和(259.53±6.30) μm,总体比较差异有统计学意义(F=32.520,P＜0.001).未发生因眼压升高行前房穿刺者,未发生眼内炎症、玻璃体腔出血、视网膜脱离及心脑血管疾病等严重并发症.结论 玻璃体腔注射康柏西普治疗高度近视CNV安全且有效,但仍需要大样本量的长期随访观察.
展开▼
